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Abstract
Background: The partner and localizer of breast cancer 2 (PALB2) is responsible for facilitating BRCA2-mediated
DNA repair by serving as a bridging molecule, acting as the physical and functional link between the breast cancer 1
(BRCA1) and breast cancer 2 (BRCA2) proteins. Truncating mutations in the PALB2 gene are rare but are thought to
be associated with increased risks of developing breast cancer in various populations.
Methods: We evaluated the contribution of PALB2 germline mutations in 122 Asian women with breast cancer, all of
whom had significant family history of breast and other cancers. Further screening for nine PALB2 mutations was
conducted in 874 Malaysian and 532 Singaporean breast cancer patients, and in 1342 unaffected Malaysian and 541
unaffected Singaporean women.
Results: By analyzing the entire coding region of PALB2, we found two novel truncating mutations and ten missense
mutations in families tested negative for BRCA1/2-mutations. One additional novel truncating PALB2 mutation was
identified in one patient through genotyping analysis. Our results indicate a low prevalence of deleterious PALB2
mutations and a specific mutation profile within the Malaysian and Singaporean populations.
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Introduction
PALB2 (PArtner and Localizer of BRCA2) is a protein that
interacts with BRCA2, stabilizing the intranuclear accumulation
of BRCA2 proteins at sites of DNA damage [1]. Biallelic loss of
PALB2 causes increased predisposition to cancers, increased
sensitivity to DNA damaging agents and Fanconi’s Anemia [2].
Germline PALB2 mutations are rare, but have been
reportedly associated with increased predisposition to breast
and other cancers. In multiple-breast cancer case families,
germline PALB2 mutations have been reported in 1.1% (10 out
of 920), 2.7% (3 out of 113), 2.0% (1 out of 50), and 0.6% (5
out of 779) of Western European families in the United
Kingdom, Finland, French-Canada, and Australasian,
respectively [3–6]. Within the familial context, germline PALB2
mutations are associated with a 2.3 to 6 fold increased risk to
breast cancer [3,7,8]. Germline PALB2 mutations have also
been reported in unselected female breast cancer cases, but at
a lower prevalence (0.9%, 18 out of 1,918 in Finnish breast
cancer cases [4]; 0.5%, 2 out of 356 in French-Canadian breast
cancer patients aged <50 years old [5]; and 0.4%, 5 out of
1,403 in Australian breast cancer patients [6]). Notably,
deleterious germline PALB2 mutations have also been reported
in pancreatic cancer cohorts from United States [9] and Europe
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[10], but its association with increased risk to ovarian cancer
cohorts remains controversial [11,12].
Germline PALB2 mutations have also been described in
other populations. In a study of Han Chinese, two carriers were
identified out of 360 (0.6%) high risk breast cancer patients
analysed [13]. Notably, three mutations (1.1%) were reported in
a study of PALB2 mutations in 279 African-American patients
[14]. Taken together, these data suggests that mutations in
PALB2 are rare and may be population-specific.
In this study, we have analysed the prevalence of PALB2
mutations in a cohort of 122 familial breast cancer cases who
have previously been tested negative for germline mutations in
BRCA1 and BRCA2 and determined the prevalence of selected
mutations in a further unselected cohort of breast cancer cases
and controls from Malaysia and Singapore.
Materials and Methods
Ethics statement
All study subjects were provided written informed consent.
Blood, demographic and family history data was collected from
breast cancer patients who consented to participate in this
study. The study was approved by the Medical Ethics
Committee of University Malaya Medical Centre (UMMC).
Study subjects
(a) Familial breast cancer patients for DNA
sequencing.  The recruitment of breast cancer patients into
the Malaysian Breast Cancer Genetic Study (MyBrCa) started
in January 2003 at the University Malaya Medical Centre in
Kuala Lumpur. All were histopathology-proven breast
carcinoma. From January 2003 to December 2010, a total of
1,220 breast cancer patients were recruited into the MyBrCa
study. All index patients were asked about family history of any
cancer, including all third degree relatives. Mutation detection
for germline BRCA1 and BRCA2 mutations was conducted on
402 individuals by direct DNA sequencing and multiple ligation
dependent probe amplification (MLPA) as previously described
[15,16]. Of these, 155 individuals were included in the PALB2
study because they were either (a) diagnosed ≤50 years old
and had at least one first- or second-degree relatives with
breast cancer; (b) diagnosed with bilateral breast cancer with
the primary cancer at age 50 or below; (c) diagnosed with male
breast cancer at any age; (d) affected with both breast and
ovarian cancers; (e) affected with both breast and pancreatic
cancers; or (f) diagnosed with breast cancer and had at least
one first-degree relative with pancreatic cancer.
(b) Malaysian breast cancer cases and controls for
genotyping.  All women with invasive breast cancer who
participated in the MyBrCa study between January 2003 and
December 2010 were included in hospital-based cohort of
breast cancer cases. Of the 1,220 breast cancer patients, 195
individuals were excluded from the study if they were either (a)
diagnosed with non-invasive carcinoma (51 cases); (b) had
missing histopathology data (74 cases); (c) from mixed
parentage or other ethnicities (20 cases); and (d) had
insufficient or low quality genomic DNA samples (52 cases). Of
the remaining individuals, a total of 874 breast cancer cases
consisting of 528 (out of 621) Chinese, 180 (out of 224) Malay
and 1166 (out of 180) Indian cases were included in the study.
Women with no breast cancer were selected from two
sources. The first was a cohort of 270 healthy individuals
attending the hospital for non-cancer related ailments and who
had no family history of cancer in first or second degree
relatives (270 healthy individuals comprising 90 Chinese, 90
Malays and 90 Indians). The second cohort comprised 1,072
women attending an opportunistic mammographic screening
programme from October 2011 to September 2012.
(c) Singaporean breast cancer cases and controls for
genotyping.  An additional 532 breast cancer cases from
Singapore Breast Cancer Cohort Project and 541 age-matched
healthy controls from the Multi-ethnic Cohort in Singapore
Consortium of Cohort Studies (SCCS) were analysed in this
study. The recruitment of Singapore Breast Cancer Cohort
Project started in April 2010 at National University Hospital and
included both prevalent and incident breast cancer cases
diagnosed from 1988 onwards. 740 patients have been
recruited between April 2010 and March 2011 and 75% of total
participants donated blood or saliva. Cases were excluded
from current analysis due to (a) from mixed parentage or other
ethnicities (13 cases), (b) male gender (1 case) and (c) had
insufficient or low quality of genomic DNA samples (7 cases).
The Multi-ethnic Cohort in SCCS consisted of approximately
12,000 community-dwelling individuals who are Singaporeans
or Singaporean Permanent Residents, 21 years and older.
Exclusion criteria were a medical history of cancer, acute
myocardial infarction or stroke, or major psychiatric morbidity
including schizophrenia, psychotic depression, and advanced
Alzheimer’s Disease. 77% of the participants who were
interviewed provided a blood sample.
PALB2 analysis
Sequencing of all the intron-exon junctions and exonic
sequences was conducted using Sanger sequencing of
genomic DNA extracted from peripheral white blood cells using
standard methods. Primer sequences were adapted from
several publications (Table S1) [2,6,17].
PALB2 Genotyping
Multiplex genotyping of seven PALB2 mutations identified in
exon 4 in this study and an additional two Asian recurrent
mutations were performed using high-throughput Sequenom
MassARRAY iPLEX platform (Sequenom Inc., San Diego,
California, USA). Mutations in other exons were identified after
the completion of the genotyping study and were therefore
excluded from analyses. All mutations identified were
confirmed by direct sequencing in an independent DNA
sample.
In silico analysis
In silico analysis of the effect of missense mutations on
protein function was determined using Polyphen-2
(Polymorphism Phenotyping version 2) [18] and SIFT (Sorting
Tolerant from Intolerant) [19,20].
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Results
Prevalence of PALB2 germline mutations in familial
breast cancer patients
Of the 155 high risk breast cancer patients selected for this
study, 20 had germline deleterious mutations in BRCA1 and 13
in BRCA2. The remaining 122 individuals tested negative for
BRCA mutations were analyzed for PALB2 germline mutations
by direct Sanger sequencing (Table 1) and 13 genetic variants
were identified (Table 2). These included two deleterious
mutations (mutation prevalence of 1.6%), ten missense
variants of unknown clinical significance and one synonymous
variant.
(a) Mutation c.1037_1041 delAAGAA; STOP 358.  This
truncating mutation was found in a Chinese woman who
developed invasive ductal carcinoma at age 38, which was
negative for the expression of the estrogen- and HER-2
receptors and positive for the expression of the progesterone-
Table 1. Characteristics of 122 individuals tested for PALB2
germline mutations.
Characteristics No %





Female breast cancer 121 99.2
Male breast cancer 1 0.8
Age at diagnosis   




> 60 3 2.5
Personal cancers   
Bilateral cancer:   
1 ≤ 50 years 21 17.2
Ovarian cancer 6 4.9
Pancreatic cancer 1 0.8
Manchester Score   
< 15 83 68.0
≥ 15 39 32.0
Family history of cancers (up to 3rd degree)   
Breast cancer 100 82.0
Ovarian cancer 3 2.5
Pancreatic cancer 2 1.6
Prostate cancer 3 2.5
No family history of either breast, ovarian, pancreatic and
prostate cancers 20 16.4
In total, 122 breast cancer patients who were tested negative for germline
mutations in BRCA1 and BRCA2 were analyzed for germline mutations in PALB2
by Sanger sequencing. Table 1 shows the distribution of index patients according
to their ethnicity, age at diagnosis and family history characteristics.
receptor. She had a maternal aunt who had breast cancer in
her 40s (Figure 1 A).
(b) Mutation c.2606 delC; S869X.  This truncating mutation
was found in a Chinese woman who developed invasive ductal
carcinoma at age 39, which was positive for the expression of
both estrogen- and progesterone-receptors and had
amplification of HER-2 receptor. Her mother was affected with
breast cancer at age 51 (Figure 1 B).
Evaluation of variants pathogenicity through case-
control analysis
Rare mutations detected from the sequencing of exon 4 of
PALB2 (n=7) and deleterious mutations that were reported to
be recurrent in other Asian populations (Chinese PALB2 c.751
C>T and PALB2 c.1250_1251 delAAinsTCT) [13] were tested
for in additional cohorts of breast cancer cases and controls by
genotyping (Table 3). The cases comprised a hospital-based
cohort of 874 breast cancer cases from Malaysia and 532
breast cancer cases from Singapore. The unaffected controls
comprised 270 women attending non-cancer related
procedures at the same hospital, 1072 women attending
mammogram screening and 541 population-based controls
from Singapore.
(a) Deleterious mutations.  One of the three deleterious
mutations evaluated was detected in the Malaysian breast
cancer cases and none were identified in the Malaysian
unaffected women, Singaporean breast cancer cases or
unaffected women (Table 3). Sequence analysis after
genotyping also revealed a novel PALB2 frameshift mutation,
PALB2 c.1050 delAACA occurring at the same amino acid as
the tested mutation, PALB2 c.1050 delAAinsTCT.
The patient with this novel deleterious mutation was a
Chinese woman who developed infiltrating ductal carcinoma at
age 62, which was positive for the expression of the estrogen
receptor and negative for the expression of the progesterone-
and HER2 receptors. Her paternal uncle was diagnosed with
nasopharyngeal cancer in his 70s (Figure 1 C).
(b) Missense variants.  PALB2 Q559R was determined to
be common in the cases and controls (33% and 27%
respectively) and this variant was also found in five
homozygote unaffected controls (data not shown) showing that
this variant is a polymorphism.
Both PALB2 I309V and PALB2 D498Y variants were
detected in more than 1% of unaffected women from the
Malaysian and Singaporean control cohorts suggesting that
these are polymorphisms. Notably, PALB2 I309V was
predicted to be benign based on SIFT and Polyphen-2 in-silico
predictions whereas PALB2 D498Y was suggested to be
possibly damaging in these in-silico analysis.
The remaining three missense mutations were determined to
be rare. PALB2 H553Q, predicted to be benign by Polyphen-2
and SIFT, was found in one Malaysian and one Singaporean
breast cancer cases (0.1% and 0.2% respectively) and none in
the controls. PALB2 P249L and PALB2 E352Q were each
found in one breast cancer case and one control. In-silico
predictions suggest that P249L may be benign while E352Q is
probably damaging.
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Four other missense mutations (PALB2 T300I, L763F,
A1017T and E1018D) were not tested in the case-control
analysis. Variants pathogenicity prediction using in-silico tools
suggest that PALB2 T300I is benign while Polyphen-2
predicted PALB2 L763F, PALB2 A1017T and PALB2 E1018D
to be probably damaging.
Discussion
In this study, we have analysed the prevalence of PALB2
mutations in a cohort of 122 familial breast cancer cases who
do not have alterations in BRCA1 or BRCA2 and found 2
(1.3%) were PALB2 carriers. Notably, we did not examine large
chromosomal rearrangements which have previously been
reported in other studies [21,22] and it is possible that these
rare genetic changes could have account for additional PALB2
carriers in our population. Although the patients in this study
comprised 3 ethnic groups (Chinese, Malay and Indian), all 3
individuals with PALB2 deleterious mutations are Chinese.
There was only 4 missense variants found in the Malay and
Indian women in this study (compared to 7 in the Chinese
women) and this is likely to be because the majority of the
women in this study are Chinese. The rarity of germline PALB2
mutations is consistent with that reported in other populations
where a mutation prevalence of 0-2% has been reported
[17,23–25].
Our study also identified 10 PALB2 missense variants, of
which 5 are novel [25,26]. Of these, 6 were tested in a case-
control analysis and our results suggest that 5 are likely to be
either benign (PALB2 Q559R, I309V, D498Y, P249L and
E352Q) or associated with a low increased risk of breast
cancer. PALB2 H553Q was found in 2 women affected with
breast cancer but not in 1,875 controls. Further analysis of this
and other variants [T300I, L763F, A1017T, E1018D] require
other methods, including in vitro functional characterization [27]
and co-segregation analyses.
Our study uncovered an unusual situation where genotyping
of a deleterious mutation (PALB2 c.1050 delAAinsTCT) [13]
revealed a distinct mutation (PALB2 c.1050 delAACA) at the
same site. Sequence alteration caused by deletion of AACA
resulted in mutant SNP that is similar to the interrogated SNP
and was therefore regarded as a positive screen. This
highlights the limitation of genotyping assay in distinguishing
distinct mutations which share a common mutant SNP and
therefore, confirmation by conventional sequencing is
necessary.
Notably, of the 3 individuals with germline deleterious PALB2
mutations, 2 have moderate family history with Manchester
score of 12 and 14 respectively, whereas one developed breast
cancer at late age in the absence of any family history of
cancer (Manchester score of 2). Indeed, by contrast to BRCA1
and BRCA2 mutation status, we found that there was no
association between PALB2 mutation status and family history
of breast, ovarian, prostate or pancreatic cancer (data not
shown). This is consistent with other studies that have also
shown no familial clustering of breast cancer in PALB2 families
compared to non-BRCA carrier families [3,14,23]. The family
members of the PALB2 carrier families were not available for
co-segregation analysis and therefore it was not possible to
determine the increased risk caused by germline mutation of
PALB2 in our population.
In summary, we found 2 germline PALB2 deleterious
mutation carriers in 122 high risk non-BRCA1 or BRCA2 breast
cancer patients by DNA sequencing and 1 germline carrier in
1406 breast cancer patients by genotyping. Our data shows
that PALB2 germline mutations are rare, and are associated
with family history of breast cancer in some, but not all families.
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Figure 1.  Pedigrees of families with germline mutations in PALB2.  (A) Family pedigree of BRC945, carrier of c.
1037_1041delAAGAA [STOP358]. (B) Family pedigree of BRC859, carrier of c.2606delC [S869X]. (C) Family pedigree of
BRC1126, carrier of c.1050delAACA [STOP353]. Index patients are indicated with an arrow while individuals affected with breast
cancer are indicated with filled symbol. Date of birth (DOB) and age of diagnosis (in bracket) foraffected individuals are indicated.
Deceased individuals are indicated with a slash.
doi: 10.1371/journal.pone.0073638.g001
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